

Resource Summary Report

Generated by [dkNET](#) on Aug 4, 2026

PerCP/Cyanine5.5 anti-human CD8

RRID:AB_2044009

Type: Antibody

Proper Citation

BioLegend Cat# 344709, RRID:AB_2044009

Antibody Information

URL: http://antibodyregistry.org/AB_2044009

Proper Citation: BioLegend Cat# 344709, RRID:AB_2044009

Target Antigen: CD8

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PerCP/Cyanine5.5 anti-human CD8

Description: This monoclonal targets CD8

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone SK1

Antibody ID: AB_2044009

Vendor: BioLegend

Catalog Number: 344709

Alternative Catalog Numbers: 344710

Record Creation Time: 20250820T015259+0000

Record Last Update: 20250820T120712+0000

Ratings and Alerts

No rating or validation information has been found for PerCP/Cyanine5.5 anti-human CD8.

No alerts have been found for PerCP/Cyanine5.5 anti-human CD8.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 10 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Liu Y, et al. (2025) Immune imbalance in the pre-ovulatory follicular microenvironment of overweight and obese women during IVF. Journal of ovarian research, 18(1), 23.

Zhang T, et al. (2025) Humanized mouse model reveals T cell ANXA2 as a potential therapeutic target in ischemic stroke. iScience, 28(5), 112302.

Webbers SDS, et al. (2025) Characterization of human CD34+ HSPC-derived neutrophils with limited myeloid-derived immunosuppressive cell activity. iScience, 28(9), 113404.

Ingels J, et al. (2024) Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum. Cell reports. Medicine, 5(5), 101516.

Klysz DD, et al. (2024) Inosine induces stemness features in CAR-T cells and enhances potency. Cancer cell, 42(2), 266.

Lin F, et al. (2024) Multimodal targeting chimeras enable integrated immunotherapy leveraging tumor-immune microenvironment. Cell, 187(26), 7470.

Bibby JA, et al. (2022) Systematic single-cell pathway analysis to characterize early T cell activation. Cell reports, 41(8), 111697.

Wang Y, et al. (2021) NAD⁺ supplement potentiates tumor-killing function by rescuing defective TUB-mediated NAMPT transcription in tumor-infiltrated T cells. Cell reports, 36(6), 109516.

Peng H, et al. (2021) Neoadjuvant FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor Cells in Patients with Pancreatic Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(24), 6761.

Peng S, et al. (2019) Sensitive Detection and Analysis of Neoantigen-Specific T Cell Populations from Tumors and Blood. Cell reports, 28(10), 2728.